According to the official website of NMPA, the arginine perindopril tablets developed by Qianyuan Pharmaceutical's subsidiary Qianyuan Baoling were approved for marketing, becoming the first domestic generic version of this product.

In 2013, China's total health expenditure was 3,186.9 billion yuan, of which the direct economic burden of hypertension accounted for 6.6%. According to statistics, the prevalence of hypertension in people over 18 years old in China has reached 27.5%, and the total number of patients is close to 300 million, but the treatment rate and control rate are only 40% and 16.9% respectively. This situation urgently needs more effective treatment strategies. The "National Primary Hypertension Prevention and Control Management Manual 2020 Edition" issued by the National Center for Cardiovascular Diseases mentioned: "Once diagnosed, it is recommended that all hypertensive patients start drug treatment immediately while intervening in lifestyle."

Drug means are crucial in the prevention and treatment of hypertension. In recent years, under the influence of changes in people's living habits and environmental factors, the number of hypertensive patients has increased year by year, and the market size of antihypertensive drugs has also increased. Among them, angiotensin converting enzyme (ACE) inhibitors occupy an important position.
Perindopril Arginine is an ACE inhibitor drug. Perindopril can be converted into the active metabolite perindoprilat. Perindopril Arginine mainly achieves blood pressure reduction by inhibiting angiotensin converting enzyme, and has good target organ protection and cardiovascular endpoint event prevention effects. Currently, the drug is used to treat hypertension, coronary artery disease and heart failure. It is understood that angiotensin converting enzyme can stimulate the secretion of aldosterone in the renal cortex and degrade bradykinin, which has the function of vasodilation, into inactive heptapeptides.

Research shows that perindopril has a long half-life, with an elimination half-life of 30-120 hours, so its antihypertensive effect lasts long, and it also has the advantages of stable antihypertensive effect and small blood pressure fluctuations, and can better Control blood pressure throughout the day, especially at night and in the early morning hours. In 2004, perindopril arginine tablets were approved for marketing in France; in 2014, the drug was introduced into China. Perindopril is currently used to treat hypertension, coronary artery disease, and heart failure, and has been included in Category B of the National Medical Insurance List.
Qianyuan Pharmaceutical's Arginine Perindopril Tablets is the first domestic product to pass the consistency evaluation of this variety.
As the number of patients with hypertension and congestive heart failure continues to increase, and the clinical recognition of ACE inhibitors continues to increase, the market prospects for related drugs are very broad. Perindopril arginine is expected to occupy an important position in the future antihypertensive drug market due to its wide application range, high safety, and significant economic benefits.

https://news.yaozh.com/archive/44645.html